NICE committee meets on Spinraza and Evrysdi

The NICE Multi Technology Assessment committee held its first discussion in November 2025. Draft recommendations are expected to be issued to consultees shortly after, with a public consultation period to follow. Both treatments remain available via Managed Access Agreements until September 2026.